ASND.O (ASND.O) News
Follow ASND.O (ASND.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Ascendis Pharma’s TransCon CNP Wins CHMP Backing for Pediatric Achondroplasia
EMA’s CHMP recommended Ascendis Pharma’s once-weekly TransCon CNP for achondroplasia in children aged 2 and older with open growth plates. A European Commission decision is expected in the fourth quarter of 2026. Subject
NEWS | Oct 17, 2026, 01:53 PM UTC
L
Ascendis Pharma's TransCon CNP Wins Positive CHMP Opinion for Childhood Achondroplasia
CHMP recommends EU authorization of Ascendis Pharma’s once-weekly TransCon CNP for achondroplasia in children aged two or older with open epiphyses. A final European Commission decision is expected in the fourth quarter
NEWS | Oct 16, 2026, 12:33 PM UTC